Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,767.60
(
-1.51%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.52
(
1.82%
)
Bitcoin
70,712.52
(
-0.74%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ariadndndough post# 139055

Friday, 03/23/2012 10:29:10 AM

Friday, March 23, 2012 10:29:10 AM

Post# of 257257
THRX/GSK—Relovair is not shaping up to be a shoo-in for the “Son of Advair” that GSK was hoping for when it inked the development deal for this product:

http://www.reuters.com/article/2012/03/23/us-glaxosmithkline-relovair-idUSBRE82M0K720120323

The new once-a-day inhaled medicine showed superiority to GSK's existing twice-daily drug Advair in one trial for chronic lung disease, but not another. That patchy record echoes results of other studies in an extensive development program.

THRX is nevertheless up slightly in trading today. The data could have been a lot worse.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now